These results confirm that, due to differences in size and avidity for the target, (m)anti-MMR Nbs can more easily penetrate dense tumor tissue, while (biv)anti-MMR Nbs can be used as blocking agent for the off-tumor MMR+ binding sites, if used at a correct dose. The gene discussed is MRC1; the disease is neoplasm.